-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sevuparin Sodium in Endotoxemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevuparin Sodium in Endotoxemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sevuparin Sodium in Endotoxemia Drug Details: Sevuparin sodium (DF-02) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemdisiran in Paroxysmal Nocturnal Hemoglobinuria Drug Details: Cemdisiran is under...
-
Product Insights
UAB Modus Group Zhytomyr Solar PV Park
UAB Modus Group Zhytomyr Solar PV Park is a solar PV project located in Zhytomyr, Ukraine. The project is owned and developed by UAB Modus Group. The project is currently active. Empower your strategies with our UAB Modus Group Zhytomyr Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays....
-
Product Insights
NewSeptic Shock – Drugs In Development, 2024
Empower your strategies with our Septic Shock – Drugs In Development, 2024 report and make more profitable business decisions. Septic shock, the most severe complication of sepsis, occurs in response to an inciting agent, which causes both pro-inflammatory and anti-inflammatory immune system activation. It involves very low blood pressure, an altered mental state, and organ dysfunction. Sepsis syndromes are often caused by multidrug-resistant bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), among others. The Septic Shock drugs in...
-
Product Insights
NewAnemia in Chronic Kidney Disease (Renal Anemia) – Drugs In Development, 2024
Empower your strategies with our Anemia in Chronic Kidney Disease (Renal Anemia) – Drugs In Development, 2024 report and make more profitable business decisions. Renal anemia is a disease in which the patient has an unusually low count of red blood cells associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, shortness...
-
Product Insights
NewSepsis – Drugs In Development, 2024
Empower your strategies with our Sepsis – Drugs In Development, 2024 report and make more profitable business decisions. Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function, and abdominal pain....
-
Product Insights
NewMalaria – Drugs In Development, 2024
Empower your strategies with our Malaria – Drugs In Development, 2024 report and make more profitable business decisions. Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea, and vomiting. Treatment includes anti-malarial medicines....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sevuparin Sodium in Malaria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevuparin Sodium in Malaria report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Sevuparin Sodium in Malaria Drug Details:Sevuparin sodium (DF-02) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vorolanib in Small-Cell Lung Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Vorolanib in Small-Cell Lung Cancer Drug Details: Vorolanib (Fumena) is an indoline derivative. It...
-
Product Insights
Modus Dev – Casa Grande Build-To-Rent Homes – Arizona
Equip yourself with the essential tools needed to make informed and profitable decisions with our Modus Dev - Casa Grande Build-To-Rent Homes - Arizona report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...